Diproqualone: Difference between revisions

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Watchedfields = changed

| verifiedrevid = 443773846

| IUPAC_name = 3-(2,3-dihydroxypropyl)-2-methyl-quinazolin-4-one

| image = Diproqualone.svg

| width = 200

<!--Clinical data-->

| tradename =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

<!--Pharmacokinetic data-->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!--Identifiers-->

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 36518-02-2

| ATC_prefix = none

| ATC_suffix =

| PubChem = 64112

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = QY7HLH8V4L

<!--Chemical data-->

| C=12 | H=14 | N=2 | O=3

| smiles = O=C1C2=CC=CC=C2N=C(C)N1CC(CO)O

'''Diproqualone''' is a [[quinazolinone]] class [[Gabaergic|GABAergic]] and is an analogue of [[methaqualone]] developed in the late 1950s by a team at Nogentaise de Produits Chimique. It was marketed primarily in France and some other European countries.<ref>{{cite journal | vauthors = Chaudharya AP, Shuklab AK, Pandeyb J, Kanta P | title = Study of developments of biologically active Quinazolinones derivatives: A review | journal = Chemistry & Biology Interface | date = 2018 | volume = 8 | issue = 2 | pages = 62–83 | url = https://cbijournal.com/paper-archive/march-april-2018-vol-2/Review-Paper-1-study-of-developments-of-biologically-active-quinazolinones-derivatives-a-review.pdf }}</ref> It has [[sedative]], [[anxiolytic]], [[antihistamine]] and [[analgesic]] properties, resulting from its agonist activity at the β subtype of the [[GABAA receptor|GABA_a receptor]], antagonist activity at all [[histamine receptor]]s, inhibition of the

[[PTGS1|cyclooxygenase-1]] enzyme, and possibly its agonist activity at both the [[sigma-1 receptor]] and [[sigma-2 receptor]] (the function of these receptors and their clinical relevance has not yet been determined). Diproqualone is used primarily for treating inflammatory pain associated with osteoarthritis and rheumatoid arthritis and more rarely, for treating insomnia, anxiety and neuralgia.

Diproqualone is the only analogue of methaqualone that is still in widespread clinical use, due to its useful anti-inflammatory and analgesic effects in addition to the sedative and anxiolytic actions common to other drugs of this class. There are still some concerns about the potential of diproqualone for abuse and overdose. So, it is not sold as a pure drug but only as the camphosulfonate salt in combination mixtures with other medicines such as [[ethenzamide]].

* [[Gamma-Aminobutyric acid]]

{{Reflist}}

{{Sedatives}}

{{GABAAR PAMs}}

[[Category:Diols]]

[[Category:GABAA receptor positive allosteric modulators]]

[[Category:Lactams]]

{{sedative-stub}}